The DiscoveryMap platform from Myriad RBM, a wholly owned subsidiary of Myriad Genetics Inc, Salt Lake City, has identified combinations of 15 protein biomarkers associated with cardiovascular (CV) events or death in people with prediabetes or early type 2 diabetes, according to a recent study.1
Riccardo Perfetti, MD, Sanofi.
“Cardiovascular diseases are one of the leading causes of deaths globally,” says Riccardo Perfetti, MD, vice president of medical affairs for global diabetes at Sanofi, Paris, which sponsored the study. “We are optimistic that as we move toward personalized medicine, cardiovascular biomarkers will help us predict future events and possibly develop tailored treatment plans for patients that will save more lives.”
For the study, researchers at the Population Health Research Institute (PHRI), Ontario, Canada, and Sanofi used Myriad RBM’s DiscoveryMap platform to evaluate 237 cardiometabolic biomarkers in serum from 8,401 participants in the completed Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial. Results of the assays were analyzed to identify biomarkers that provided better estimates of the risk of future CV events or death than could be estimated from standard clinical and biochemical data alone. The analysis identified a novel combination of 10 biomarkers that, when added to clinical risk factors, can find people with dysglycemia who are at higher risk of heart attack, stroke, or CV death. Moreover, these 10 biomarkers, plus an additional five, had the greatest impact on the ability to predict death.
“Our study is one of the largest scientific investigations in history to identify specific cardiovascular biomarkers associated with serious cardiovascular outcomes, including heart attacks, strokes, and death,” says Hertzel Gerstein, MD, lead study investigator and deputy director at PHRI. “Our results highlight the potential value of cardiovascular biomarkers for identifying people with dysglycemia at the highest risk of future events.”
DiscoveryMap is a comprehensive, quantitative, immunoassay service product that measures more than 300 human proteins. It is the culmination of 15 years of assay development for acute phase reactants, angiogenesis markers, cancer markers, central nervous system biomarkers, chemokines, cytokines, growth factors, hormones, kidney damage markers, metabolic markers, tissue remodeling proteins, and other important circulating proteins.
Ralph McDade, PhD, Myriad RBM.
“This is another demonstration that our DiscoveryMap technology can successfully identify panels of biomarkers with important diagnostic and prognostic applications,” says Ralph McDade, PhD, president of Myriad RBM. “We believe that the protein biomarkers characterized by the PHRI and Sanofi teams may identify people at higher risk for cardiovascular events. Based on these very encouraging findings, we are pursuing additional research collaborations to further develop panels of protein biomarkers with application for cardiometabolic disorders.”
ORIGIN was a 7-year landmark cardiovascular outcomes trial, evaluating insulin glargine versus standard care in more than 12,500 individuals who were at high CV risk with prediabetes or early type 2 diabetes mellitus. ORIGIN was sponsored by Sanofi, and was designed, conducted, and analyzed by PHRI and its international network of diabetes and cardiovascular disease experts.
For more information visit Myriad RBM.
REFERENCE
- Gerstein HC, Paré G, McQueen MJ, et al. Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia. Circulation. 2015;132(24):2297–2304; doi: 10.1161/circulationaha.115.015744.
